Aidi injection reduces doxorubicin-induced cardiotoxicity by inhibiting carbonyl reductase 1 expression
Context Aidi injection (ADI), a traditional Chinese medicine antitumor injection, is usually combined with doxorubicin (DOX) for the treatment of malignant tumours. The cardiotoxicity of DOX is ameliorated by ADI in the clinic. However, the relevant mechanism is unknown.Objective To investigate the...
Main Authors: | Yuan Lu, Wen Liu, Ting Lv, Yanli Wang, Ting Liu, Yi Chen, Yang Jin, Jin Huang, Lin Zheng, Yong Huang, Yan He, Yongjun Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | Pharmaceutical Biology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/13880209.2022.2110127 |
Similar Items
-
Analysis of the Doxorubicin and Doxorubicinol in the Plasma of Breast Cancer Patients for Monitoring the Toxicity of Doxorubicin
by: Harahap Y, et al.
Published: (2020-08-01) -
Comparative pharmacokinetics of free doxorubicin and a liposomal formulation in cats following intravenous administration
by: Yu Liu, et al.
Published: (2024-01-01) -
Local penetration of doxorubicin via intrahepatic implantation of PLGA based doxorubicin-loaded implants
by: Li Gao, et al.
Published: (2019-01-01) -
Determination of doxorubicin in plasma and tissues of mice by UPLC-MS/MS and its application to pharmacokinetic study
by: Zhilin Jin, et al.
Published: (2024-08-01) -
Development and validation of a UPLC-MS/MS method for simultaneous detection of doxorubicin and sorafenib in plasma: Application to pharmacokinetic studies in rats
by: Alanoud Altalal, et al.
Published: (2023-07-01)